What Was Approved?
On August 25, 2026, the U.S. Food and Drug Administration approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia, or wAIHA, in adults and pediatric patients 12 years of age and older who are currently or previously treated with corticosteroids.
Imaavy is the first FDA-approved treatment specifically for wAIHA.
What Is Warm Autoimmune Hemolytic Anemia?
Warm autoimmune hemolytic anemia is a rare blood disorder in which the immune system mistakenly targets and destroys the body’s own red blood cells.
This process is called hemolysis.
When red blood cells are destroyed faster than the body can replace them, anemia can develop.
Why Is It Called “Warm” Autoimmune Hemolytic Anemia?
In wAIHA, the antibodies involved are most active at normal body temperature.
The disease commonly involves IgG antibodies that attach to red blood cells and mark them for destruction by the immune system.
How Does Imaavy Work?
Imaavy is a neonatal Fc receptor, or FcRn, blocker.
By blocking FcRn, the medicine reduces circulating levels of IgG antibodies.
Because IgG autoantibodies play an important role in wAIHA, lowering these antibodies may reduce immune-mediated destruction of red blood cells.
How Is Imaavy Given?
Imaavy is administered by intravenous infusion by a healthcare professional.
The exact dose and schedule depend on the FDA-approved prescribing information and the patient’s clinical situation.
What Did the Clinical Trial Show?
FDA based the approval on a randomized, double-blind, placebo-controlled study involving 118 patients with wAIHA.
One of the main measures of effectiveness was a durable hemoglobin response, meaning a sustained improvement in hemoglobin levels.
In the study, 24% of patients receiving Imaavy 30 mg/kg every 4 weeks achieved a durable hemoglobin response, compared with 8% of patients receiving placebo.
What Are the Common Side Effects?
According to the FDA, common adverse reactions in patients with wAIHA included:
- Peripheral edema
- Fatigue
- Diarrhea
- Fever
Infusion-related reactions can also occur and may include symptoms such as headache, nausea, dizziness, chills, rash, or flu-like symptoms.
Who Is This Treatment For?
Imaavy is approved for:
- Adults with wAIHA
- Pediatric patients 12 years and older
- Patients who are currently receiving or have previously received corticosteroid treatment
Treatment decisions should be individualized based on disease severity, prior treatment, other medical conditions, and overall risk.
Why Is This Approval Important?
Until this approval, there was no FDA-approved medication specifically indicated for warm autoimmune hemolytic anemia.
Imaavy provides a new treatment option for patients with a rare disease that can cause persistent anemia, fatigue, and other complications related to red blood cell destruction.
Bottom Line
Imaavy (nipocalimab-aahu) is the first FDA-approved treatment specifically for warm autoimmune hemolytic anemia.
It provides a new option for adults and patients 12 years and older who have been treated with corticosteroids, but treatment should be guided by a specialist familiar with autoimmune blood disorders.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia, August 25, 2026.
- U.S. Food and Drug Administration (FDA) — Notable Approvals, August 2026.
- U.S. Food and Drug Administration (FDA) — Rare Disease Drug Approvals.